Caris Life Sciences (NASDAQ:CAI) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Caris Life Sciences (NASDAQ:CAI) in a research note issued to investors on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $28.00 target price on the stock.

Several other research analysts have also recently issued reports on the stock. The Goldman Sachs Group initiated coverage on shares of Caris Life Sciences in a report on Wednesday, April 1st. They set a “buy” rating and a $27.00 target price on the stock. Robert W. Baird increased their target price on shares of Caris Life Sciences from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. Piper Sandler initiated coverage on shares of Caris Life Sciences in a report on Friday. They set a “neutral” rating and a $21.00 target price on the stock. Canaccord Genuity Group dropped their target price on shares of Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating on the stock in a report on Friday, March 13th. Finally, BTIG Research dropped their target price on shares of Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $28.86.

Caris Life Sciences Trading Up 6.0%

Shares of CAI opened at $19.13 on Monday. The stock has a market capitalization of $5.41 billion and a price-to-earnings ratio of -106.28. Caris Life Sciences has a 12-month low of $16.28 and a 12-month high of $42.50. The company has a debt-to-equity ratio of 0.66, a current ratio of 7.85 and a quick ratio of 7.35. The company’s fifty day moving average is $19.47.

Caris Life Sciences (NASDAQ:CAI) last issued its earnings results on Thursday, February 26th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.27. The company had revenue of $292.89 million for the quarter, compared to analysts’ expectations of $281.00 million. The firm’s revenue for the quarter was up 125.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.73) earnings per share.

Institutional Trading of Caris Life Sciences

Several hedge funds have recently modified their holdings of the company. Hsbc Holdings PLC purchased a new stake in shares of Caris Life Sciences during the fourth quarter valued at about $261,000. PEAK6 LLC lifted its position in shares of Caris Life Sciences by 6.9% during the fourth quarter. PEAK6 LLC now owns 24,800 shares of the company’s stock valued at $669,000 after buying an additional 1,600 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Caris Life Sciences by 14.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock valued at $248,377,000 after buying an additional 1,180,200 shares during the last quarter. Invesco Ltd. lifted its position in shares of Caris Life Sciences by 28.5% during the fourth quarter. Invesco Ltd. now owns 1,033,115 shares of the company’s stock valued at $27,873,000 after buying an additional 229,313 shares during the last quarter. Finally, VARCOV Co. purchased a new stake in shares of Caris Life Sciences during the fourth quarter valued at about $1,080,000.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.